Our top Best Buys this month tried direct-to-consumer and sales slumped severely. Today, though, the company is helmed by a new and sensible CEO whose top priority has been getting its product off the internet and back into major retailers, with encouraging results that are reflected in recent earnings.
Some rare companies are so dominant in the marketplace that their brands actually become the business. The company featured this month is so dominant in its field that it should have been included in the “Legal Monopolies” portfolio category, but that legality is being called into question by the U.S. federal government.
The potential for a new biotech bull market means there has never been a better time to become a Biotech Frontiers subscriber. But that’s not the only reason to consider joining Erez Kalir’s service today… Read on to learn more!
In this week’s issue of The Big Secret On Wall Street, we perform a brief market analysis and a comprehensive portfolio review on six of our holdings as well as offering actions to take.
We have added two new companies to our Best Buys list of stocks that we feel are at a price that investors should seize on now – a pharma company and a tech firm join the cutting-edge tobacco company.
Legal monopolies all have similar traits: They have dominant market share, they have enviable pricing power, and given a lack of alternatives for customers, these companies likely have highly predictable and mostly recurring revenue streams. All of that means big profit margins that flow to the bottom line.
In this week’s issue of The Big Secret On Wall Street, we provide excerpts from recommendations of the three top-performing Best Buys – each company held a position in our Best Buys feature for an extended period, generating returns that outperformed the rest of the portfolio and the overall market, represented by the S&P 500.
In this week’s issue of The Big Secret On Wall Street, we deliver our first-ever report card. Given our focus on long-term investments, the three-year mark has provided an adequate track record to officially show readers how we are doing.
In this week’s issue of The Big Secret On Wall Street, we perform a comprehensive portfolio review. Given our focus on long-term investments, the three-year mark has provided an adequate track record to officially see how we are doing.
Two of the companies we are including as the 3 “Best Buys” in this issue offer the best defense against a slowing economy. The third is a rapidly expanding business that will soon become the leading exporter of cheap American fossil fuels, and offers an idiosyncratic growth story that should thrive regardless of the macro environment. We recommend investors put these names at the top of their “buy” list.